Retrospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Mar 7, 2015; 21(9): 2700-2710
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2700
Table 1 Primers used in this study
Primer
KRASForward5’-GGCCTGCTGAAAATGACTGA-3’
Reverse5’-GTTGGATCATATTCGTCCAC-3’
BRAFForward5’-CCTTTACTTACTACACCTCAG-3’
Reverse5’-CATCCACAAAATGGATCCAG-3’
BAT25Forward15’-TCGCCTCCAAGAATGTAAGT-3’
Reverse5’-TCTGCATTTTAACTATGGCTC-3’
BAT26Forward15’-TGACTACTTTTGACTTCAGCC-3’
Reverse5’-AACCATTCAACATTTTTAACCC-3’
D2S123Forward15’-GAAACAGGATCCTGCCTTTA-3’
Reverse5’-GGACTTTCCACCTATGGGAC-3’
D5S346Forward15’-GACTCACTCTAGTATAAATCGGG-3’
Reverse5’-GAGCAGATAAGACAGTATTACTAGTT-3’
D17S250Forward15’-GGGAAGAATCAAATAGACAAT-3’
Reverse5’-GCTGGCCATATATATATTTAAACC-3’
Table 2 Clinicopathological findings of all 47 cases of small intestinal adenocarcinomas n (%)
All cases (n = 47)
Age (yr)
Mean (range)59.9 (23-87)1
Gender
Male29
Female18
Gross appearance
Polypoid12
Ulcerative35
Size (cm) (mean)5.13
Location
Duodenum14
Jejunum21
Ileum12
Histological subtype
Tubular233
Poorly9
Mucinous5
Invasion depth3
T12
T24
T318
T423
Lymphatic permeation33 (70)
Venous invasion12 (26)
Adenomatous component3 (6)
Table 3 Clinicopathological features and expression of mucin core proteins and CD10
MUC5AC
MUC6
MUC2
CD10
Positive(n = 12)Negative(n = 35)Positive(n = 4)Negative(n = 43)Positive(n = 20)Negative(n = 27)Positive(n = 7)Negative(n = 40)
Age (yr)
Mean ± SD63.4 ± 15.1158.8 ± 16.576.3 ± 10.0158.7 ± 15.962.3 ± 15.358.0 ± 16.7160.1 ± 15.159.8 ± 16.51
(range)(35-85)(23-87)(67-87)(23-85)(38-87)(23-81)(38-87)(23-85)
Gender (male/female)10/219/163/126/179/1118/93/427/14
Gross appearance
(polypoid/ulcerated)3/99/262/210/336/146/214/3a8/32a
Size (cm)5.3 ± 2.25.1 ± 1.95.0 ± 1.85.1 ± 2.05.7 ± 1.6a4.7 ± 2.2a5.9 ± 1.4a5.0 ± 2.1a
Location
(duodenum/jejunum/ileum)2/5/512/16/72/1/112/20/116/11/38/10/94/2/110/19/11
Histological subtype
(tubular2/poorly/mucinous)6/3/327/6/23/0/130/9/413/2/510/7/07/0/029/9/5
Invasion depth3
T10202202a0a
T22222222a2a
T32160186121a17a
T481522110132a21a
Lymphatic permeation n (%)10 (83)23 (66)2 (50)31 (72)12 (60)21 (78)3 (43)30 (75)
Venous invasion n (%)3 (25)9 (26)1 (25)11 (26)5 (25)7 (26)2 (29)10 (25)
Adenomatous component n (%)0 (0)3 (9)1 (25)2 (5)3 (15)a0 (0)a2 (29)a1 (3)a
Table 4 Summarized data of microsatellite instability status, expression of mismatch repair proteins and KRAS mutations
MSIExpression of MMR protein
KRAS mutationbase exchange (codon)AgeGender
MLH1MSH2
Case 6MSI-H++-55M
Case 36MSI-H+--85M
Case 31MSI-H-+-67M
Case 34MSI-H++-71M
Case 12MSI-L++GGT>GAT(12)69M
Case 28MSI-L+--41M
Case 24MSI-L++-60M
Case 40MSI-L++-35M
Case 25MSI-L++-53F
Case 5MSI-L++-23F
Case 44MSI-L++-87F
Case 38MSI-L++-67F
Case 41MSS++GGC>GAC(13)45F
Case 20MSS++GGT>GAT(12)59F
Case 46MSS++GGT>GTT(12)40F
Table 5 Clinicopathological features, microsatellite instability status and KRAS mutation
MSI
KRAS
MSI-H(n = 4)MSI-L/MSS(n = 30)Mutational type(n = 4)Wild type(n = 33)
Age (yr)69.5 ± 12.359.6 ± 15.9153.3 ± 13.260.8 ± 16.21
Gender (male/female)4/016/141/322/11
Gross appearance (polypoid/ulcerated)1/36/242/29/24
Size (cm)7.7 ± 1.1a5.1 ± 2.0a4.4 ± 1.05.5 ± 2.0
Location (duodenum/jejunum/ileum)0/2/27/15/81/2/19/15/9
Histological subtype (tubular2/poorly/mucinous)2/0/222/6/24/0/022/8/3
Invasion depth3
T10101
T20203
T3213113
T4214315
Lymphatic permeation n (%)3 (75)23 (77)4 (100)22 (67)
Venous invasion n (%)1 (25)9 (30)1 (25)10 (30)
Adenomatous component n (%)0 (0)1 (3)0 (0)2 (6)
Table 6 Summarized data of 4 small intestinal adenocarcinomas with co-expression of MUC5AC and MUC2
AgeGenderLocationHistological subtypeInvasion depthLymphatic permeationVenous invasionLymph node metastasisMSI
case 655mJejunumTubularT3---MSI-H
case 2961mJejunumMucinousT4+-No dataMSS
case 3167mIleumMucinousT4+-No dataMSI-H
case 3685mIleumMucinousT4+--MSI-H